Researched applications The published preclinical literature documents the effects of BPC-157 in the following areas (mostly in animal models): Tendon and ligament healing , Achilles tendon, medial collateral ligament (MCL, the ligament on the inner side of the knee), tendinopathy models Muscle injuries , quadriceps (front thigh), gastrocnemius (calf muscle), transections and contusions Bone and joint healing , osteoarthritis models, fracture healing, periodontal tissues (around the teeth) Gastrointestinal diseases , gastric lesions caused by alcohol or NSAIDs (ibuprofen, diclofenac), colitis, IBD models (Crohns disease), fistulas Hepatoprotection , protection of the liver against toxic damage (paracetamol overdose, CCl, alcohol) Vascular healing , endothelial dysfunction, thromboses, healing of vascular anastomoses after surgery, thrombocytopenia (low platelet count) Skin wounds , acute as well as diabetic wounds, burns Nerve regeneration , peripheral (sciatic nerve crush) as well as central (cerebral ischemia models, i.e
Cardone, Platelet Rich Placebo?: Evidence for Platelet Rich Plasma in the Treatment of Tendinopathy and Augmentation of Tendon Repair, Bulletin of the Hospital for Joint Diseases 71 (2013): 57
10.1086/681161 Int
My understanding (Im not a legal expert, so dont take my word for it) is that if Evolv ever wants EV1 in beverages or bars, a GRAS evaluation/notice would likely be needed
history of excessive alcohol use, alcohol abuse, or alcohol use disorder or history of alcohol-related disorders
